Introduction: rewriting disease at the information level

Most conventional medicines work by modifying the behavior of proteins — blocking a receptor, inhibiting an enzyme, or altering downstream signaling pathways. But proteins are the end of the biological information chain. Their behavior is determined upstream, by how RNA is spliced, translated, and regulated.

Oligonucleotide therapies intervene at the level of genetic information, not protein activity. These drugs are short, synthetic DNA or RNA sequences designed to modulate gene expression, silence harmful transcripts, correct defective splicing, or restore missing protein production. They treat disease by reshaping cellular messages, rather than reacting to downstream biochemical damage.

This makes oligonucleotides one of the most important emerging modalities in precision medicine, especially for genetic disorders and rare diseases historically considered “undruggable.”

What are oligonucleotide therapies?

Oligonucleotide therapies are short, sequence-defined nucleic acids (typically 15–30 nucleotides) engineered to bind complementary RNA through Watson–Crick base pairing. Once bound, they may:

• Silence a disease-driving transcript (siRNA)
• Modify RNA splicing to restore protein production (antisense oligonucleotides)
• Replace protein expression (mRNA therapeutics)
• Bind protein targets directly (aptamers)
• Alter transcriptional signaling (DNA-based oligomers)

Because their specificity arises from sequence complementarity rather than protein binding pockets, oligonucleotides can target genetic mechanisms that small molecules and antibodies cannot.

Key classes of oligonucleotide therapeutics

Case example: antisense therapy in spinal muscular atrophy (SMA)

Spinal muscular atrophy (SMA) is caused by insufficient SMN protein due to dysfunction of the SMN1 gene. Patients retain a backup gene, SMN2, but a splicing error prevents it from producing functional protein.

Nusinersen (Spinraza) is an antisense oligonucleotide (ASO) designed to correct SMN2 splicing by promoting exon 7 inclusion, effectively converting SMN2 into a functional replacement gene.

In a landmark clinical trial, nusinersen improved survival, respiratory independence, and motor development in infants with SMA
(Finkel et al., New England Journal of Medicine, 2017).

This result demonstrated that rewriting RNA can rewrite disease progression.

Case example: RNA interference therapy in hereditary transthyretin amyloidosis (hATTR)

Hereditary transthyretin amyloidosis is caused by misfolded transthyretin (TTR) protein that forms amyloid deposits in nerves and organs. Patisiran applies RNA interference (RNAi) to silence TTR production directly at the transcript level.

Delivered via lipid nanoparticle (LNP) formulation, patisiran engages the RISC complex to degrade TTR mRNA.

In clinical trials, patisiran produced sustained reduction in TTR levels and clinically meaningful improvement in neuropathy
(Adams et al., New England Journal of Medicine, 2018).

This validated RNAi as a scalable, systemically deliverable therapeutic mechanism.

How oligonucleotide therapies enable precision medicine

One of the defining strengths of oligonucleotide therapeutics is their programmability. Because they act on RNA, designing a therapy requires only the sequence of the target transcript, not structural knowledge of the resulting protein. This enables therapeutic development for mutations, splice errors, and genetic loss-of-function mechanisms where conventional drugs cannot act
(Crooke et al., Cell Metabolism, 2018).

Advantages include:

• Rapid sequence-driven design
• Ability to target undruggable proteins and regulatory elements
• Reversible dosing, unlike permanent gene editing
• Suitability for rare and ultra-rare disease populations

This shifts medicine from population-based treatment to mutation-level intervention.

Instead of asking “What protein should we inhibit?”
Precision medicine asks “What message should we rewrite?”

Challenges shaping the field

While oligonucleotide therapies have demonstrated clear clinical success, several scientific and translational challenges shape their development trajectory.

1. Delivery to the right tissues

Oligonucleotides are large, negatively charged molecules that do not easily cross cell membranes. They require targeted delivery strategies such as:

• GalNAc–conjugation for precise hepatocyte uptake
• Intrathecal administration for central nervous system access
• Lipid nanoparticles (LNPs) to enable systemic circulation

Each delivery route imposes trade-offs in dose frequency, convenience, and broad accessibility
(Juliano, Nucleic Acids Research, 2016).

2. Stability and persistence in circulation

RNA is naturally prone to rapid degradation. To achieve therapeutic durability, oligonucleotides require:

• Backbone modifications (e.g., phosphorothioate linkages)
• Nucleobase and sugar analog substitution
• End-cap protection against exonuclease digestion

These chemical modifications influence not only stability, but immune activation, biodistribution, and cellular uptake, requiring careful tuning.

3. Specificity and off-target interactions

While oligonucleotides are designed for sequence precision, partial complementarity with unintended transcripts can produce off-target effects. Preventing this requires:

Continue reading below...

WebinarsUnlocking insights into rare kidney disease through genomic data

Large-scale clinicogenomic data sheds light on the biology of rare kidney disorders and opens doors to new treatment possibilities.

Read More

• Computational transcriptome-wide binding prediction
• Biophysical affinity modeling
• Deep RNA expression profiling during preclinical development

4. Tissue penetration and cellular trafficking

Even when correctly delivered to the right organ, oligonucleotides must navigate:

• Cellular uptake pathways
• Endosomal escape
• Nuclear vs. cytoplasmic localization, depending on the mechanism of action

These steps determine how much drug reaches its intracellular target, and how often patients must be dosed.

Future outlook: individualized genetic medicine

The next wave of oligonucleotide therapeutics is defined by tailored sequence design:

• N-of-1 antisense therapies for ultra-rare genetic disorders
• mRNA therapeutics for enzyme restoration and regenerative repair
• Self-amplifying RNA systems to reduce dose frequency
• Hybrid antibody–oligonucleotide and nanoparticle–oligonucleotide platforms for cell-specific targeting

As genome sequencing becomes routine, treatment design may increasingly follow:

Identify the mutation → Design the oligonucleotide → Restore function.

This model is no longer hypothetical — it is being implemented in active clinical research programs.

Conclusion

Oligonucleotide therapies represent a fundamental shift from targeting proteins to targeting the instructions that create them. They open treatment pathways for genetic diseases once considered unreachable and enable a level of precision previously unattainable with conventional drug platforms.

The future of medicine may not rely on discovering new molecules — but on writing new biological messages.

References

1. Finkel RS, Mercuri E, Darras BT, et al. Nusinersen versus sham control in infantile-onset spinal muscular atrophy. New England Journal of Medicine. 2017;377(18):1723–1732.

2. Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Research. 2016;44(14):6518–6548.

3. Adams D, Gonzalez-Duarte A, O’Riordan WD, et al. Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. New England Journal of Medicine. 2018;379(1):11–21.

4. Crooke ST, Witztum JL, Bennett CF, Baker BF. RNA-targeted therapeutics. Cell Metabolism. 2018;27(4):714–739.

5. Corey DR. Nucleic acid drugs: A key new class of biologics. Science. 2020;367(6481):141–142.